
Gene-Swaps Could Let Influenza Jump Species
A seemingly ingenious and sneaky way for viruses to make these leaps is by swapping genetic material with other flu strains. Called reassortment, this exchange happens when a person or animal is infected with two types of flu virus at the same time. While replicating inside the host cell, the viruses can grab bits of each other's genetic code and incorporate them into their own gene sequences.
Reassortment is much less common than small mutations that change the flu year to year, but it's important: at least three of the last four human flu pandemics have involved reassortment.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
'Reassortment has played a major, major role in the emergence of pandemic influenza,' says Daniel Perez, a professor of poultry medicine at the University of Georgia College of Veterinary Medicine, who studies how flu moves between species.
The past century saw four flu pandemics. The first was the notorious 1918 Great Influenza, which killed around 50 million people. The second was in 1957, when a new flu killed between one million and four million people worldwide. In 1968 another new flu emerged, killing another one million to four million people. Finally, in 2009, a novel swine flu appeared, killing between 151,000 and 575,000 people that year.
Flu viruses are categorized by two types of proteins on their surfaces, hemagglutinin (HA) and neuraminidase (NA). These proteins each have multiple subtypes, which is why you'll see labels such as H1N1 or H5N1. The H refers to the HA protein type, and the N refers to the type of NA protein. The Great Influenza that swept the globe during World War I was an H1N1 flu that likely emerged in Kansas. Its descendants circulated in both humans and pigs until 1957, when it was suddenly replaced in humans by an H2N2 flu. This new virus first popped up in southern China. Its main genetic backbone belonged to the 1918 flu, Perez says, but it had acquired three new gene sequences from an avian flu, swapping its HA and NA proteins for new subtypes. For reasons not completely understood, this new H2N2 wiped out H1N1 in humans for decades—H1N1 wouldn't be seen again in people until 1977.
The 1968 pandemic was another reassortment event. This time, the H2N2 that was circulating in humans swapped genes with an H3N2 avian influenza, probably somewhere in China. (The first identified outbreak was in Hong Kong.)
Then came the 2009 pandemic, a true 'globalized pandemic,' Perez says. In the early 2000s there had been a few sporadic human infections in the U.S. with so-called triple-reassorted flu viruses that contained genes from human, avian and swine influenzas. These cases were rare and mostly in people who worked on pig farms; these viruses didn't transmit from human to human. That changed in 2009 when the triple-reassorted viruses picked up new genes from a Eurasian swine flu. 'It's a perfect example of globalization,' Perez says, 'because the virus contains not only gene segments from an avian flu, from a swine flu [and] from a human flu but also from very different geographical locations.'
The reassortment of flu viruses that infect different species fortunately happens relatively infrequently, says Charlotte Kristensen, a postdoctoral researcher in veterinary clinical microbiology at the University of Copenhagen. 'It has to be two different viruses infecting the same host cell, and the reassortment has to be successful. And it's not always like the gene segments are compatible,' she says.
Such reassortment happens all the time between avian flu strains that infect birds, says Yuan Liang, also a University of Copenhagen veterinary clinical microbiology postdoctoral researcher. 'Especially since 2020, there have been a lot of new variants emerging because of reassortments' in birds, Liang says.
The various strains of H5N1 circulating now in wild birds, domestic poultry and dairy cows have yet to cause a pandemic in people. It's hard to say whether the virus will stay mostly in animals or whether we're now in a period like the one before the 2009 flu pandemic, when farmworkers occasionally came down with a reassorted virus that would later gain the gene sequences it needed to spread from person to person. No one expect H5N1 to take hold in dairy cattle, Liang says, so the question now is what new, unexpected step this virus might take.
'This whole situation really highlights how little we know and how complex it is,' Kristensen says.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Scientific American
5 days ago
- Scientific American
Gene-Swaps Could Let Influenza Jump Species
Influenza viruses are shifty entities. They accumulate small genetic changes on a regular basis, necessitating yearly updates to the flu vaccines because the prior year's strain may not look much like the following year's. But they can also make sudden leaps by incurring big genetic changes that may allow them to jump from one animal species to another or to humans. A seemingly ingenious and sneaky way for viruses to make these leaps is by swapping genetic material with other flu strains. Called reassortment, this exchange happens when a person or animal is infected with two types of flu virus at the same time. While replicating inside the host cell, the viruses can grab bits of each other's genetic code and incorporate them into their own gene sequences. Reassortment is much less common than small mutations that change the flu year to year, but it's important: at least three of the last four human flu pandemics have involved reassortment. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. 'Reassortment has played a major, major role in the emergence of pandemic influenza,' says Daniel Perez, a professor of poultry medicine at the University of Georgia College of Veterinary Medicine, who studies how flu moves between species. The past century saw four flu pandemics. The first was the notorious 1918 Great Influenza, which killed around 50 million people. The second was in 1957, when a new flu killed between one million and four million people worldwide. In 1968 another new flu emerged, killing another one million to four million people. Finally, in 2009, a novel swine flu appeared, killing between 151,000 and 575,000 people that year. Flu viruses are categorized by two types of proteins on their surfaces, hemagglutinin (HA) and neuraminidase (NA). These proteins each have multiple subtypes, which is why you'll see labels such as H1N1 or H5N1. The H refers to the HA protein type, and the N refers to the type of NA protein. The Great Influenza that swept the globe during World War I was an H1N1 flu that likely emerged in Kansas. Its descendants circulated in both humans and pigs until 1957, when it was suddenly replaced in humans by an H2N2 flu. This new virus first popped up in southern China. Its main genetic backbone belonged to the 1918 flu, Perez says, but it had acquired three new gene sequences from an avian flu, swapping its HA and NA proteins for new subtypes. For reasons not completely understood, this new H2N2 wiped out H1N1 in humans for decades—H1N1 wouldn't be seen again in people until 1977. The 1968 pandemic was another reassortment event. This time, the H2N2 that was circulating in humans swapped genes with an H3N2 avian influenza, probably somewhere in China. (The first identified outbreak was in Hong Kong.) Then came the 2009 pandemic, a true 'globalized pandemic,' Perez says. In the early 2000s there had been a few sporadic human infections in the U.S. with so-called triple-reassorted flu viruses that contained genes from human, avian and swine influenzas. These cases were rare and mostly in people who worked on pig farms; these viruses didn't transmit from human to human. That changed in 2009 when the triple-reassorted viruses picked up new genes from a Eurasian swine flu. 'It's a perfect example of globalization,' Perez says, 'because the virus contains not only gene segments from an avian flu, from a swine flu [and] from a human flu but also from very different geographical locations.' The reassortment of flu viruses that infect different species fortunately happens relatively infrequently, says Charlotte Kristensen, a postdoctoral researcher in veterinary clinical microbiology at the University of Copenhagen. 'It has to be two different viruses infecting the same host cell, and the reassortment has to be successful. And it's not always like the gene segments are compatible,' she says. Such reassortment happens all the time between avian flu strains that infect birds, says Yuan Liang, also a University of Copenhagen veterinary clinical microbiology postdoctoral researcher. 'Especially since 2020, there have been a lot of new variants emerging because of reassortments' in birds, Liang says. The various strains of H5N1 circulating now in wild birds, domestic poultry and dairy cows have yet to cause a pandemic in people. It's hard to say whether the virus will stay mostly in animals or whether we're now in a period like the one before the 2009 flu pandemic, when farmworkers occasionally came down with a reassorted virus that would later gain the gene sequences it needed to spread from person to person. No one expect H5N1 to take hold in dairy cattle, Liang says, so the question now is what new, unexpected step this virus might take. 'This whole situation really highlights how little we know and how complex it is,' Kristensen says.


Business Wire
10-07-2025
- Business Wire
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. According to the US Centers for Disease Control and Prevention (CDC), annual influenza vaccination is the first and most important action recommended to reduce the risk of flu and its potentially serious outcomes. Ideally, vaccination should occur by the end of October, but people can continue to get vaccinated as long as the flu poses a threat. 1 CDC recommends an annual flu vaccination for anyone aged six months or older who does not have contraindications. 1,2 CDC estimates that from October 1, 2024, through May 17, 2025, there were 47 – 82 million flu illnesses, 610,000 – 1.3 million flu hospitalizations and 27,000 – 130,000 flu deaths. 3 The 2024-25 flu season was the first season since 2017-18 that the CDC classified as high severity, and preliminary CDC estimates indicate that it was the worst flu season (based on flu illnesses, hospitalizations and deaths) the US has seen in the last 15 years. 4,5 For egg-based influenza vaccines for the 2025-26 flu season in the Northern Hemisphere, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended including an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Croatia/10136RV/2023 (H3N2)-like virus and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus. 6 About Influenza The flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat and sometimes the lungs. It can cause mild-to-severe illness and at times can lead to death. 7 Anyone, including healthy people, can get the flu, however, it can be more serious for children younger than five, adults 65 years and older, people with a body mass index (BMI) of 40 kg/m 2 or higher, pregnant women and people with pre-existing chronic health conditions, such as asthma, diabetes and heart disease. 7 For more information about the flu, visit Indication for FLUARIX and FLULAVAL FLUARIX and FLULAVAL are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccines. FLUARIX and FLULAVAL are approved for use in persons aged 6 months and older. Important Safety Information for FLUARIX and FLULAVAL Do not administer FLUARIX or FLULAVAL to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX or FLULAVAL should be based on careful consideration of the potential benefits and risks. Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX and FLULAVAL. Procedures should be in place to avoid injury from fainting. Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUARIX and FLULAVAL. If FLUARIX or FLULAVAL is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons. The most common solicited local adverse reactions with FLUARIX in adults were pain and redness, and the most common systemic adverse reactions were muscle aches, fatigue, and headache. In children aged 5 through 17 years, the most common solicited local adverse reactions were pain, redness, and swelling, and the most common systemic adverse reactions were muscle aches, fatigue, and headache. In children aged 3 through 4 years, the most common solicited local adverse reactions were pain, redness, and swelling, and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. In children aged 6 through 35 months who received FLUARIX QUADRIVALENT, the most common solicited local adverse reactions were pain and redness, and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. The most common solicited local adverse reactions with FLULAVAL in adults were pain, redness, and swelling, and the most common solicited systemic adverse reactions were fatigue, headache, and muscle aches/arthralgia. In children aged 3 through 17 years, the most common solicited local adverse reaction was pain. In children aged 3 through 4 years, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children aged 5 through 17 years, the most common solicited systemic adverse reactions were muscle aches, headache, and fatigue. In children aged 6 through 35 months who received FLULAVAL QUADRIVALENT, the most common solicited local adverse reaction was pain, and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. Vaccination with FLUARIX or FLULAVAL may not result in protection of all vaccine recipients. Please see full Prescribing Information for FLUARIX and for FLULAVAL. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in GSK's Annual Report on Form 20-F for 2024. Registered in England & Wales: No. 3888792 References
Yahoo
09-07-2025
- Yahoo
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8. 100% virus neutralization against 33 current field isolates.1 Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4 TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines. GREENFIELD, Ind., July 9, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan Ultra CIV completes Elanco's Tru Portfolio of comfortable and convenient combination vaccines made with PureFil™ Technology, an exclusive process for creating highly purified vaccines designed to reduce adverse reactions and deliver better experiences. In Canine Influenza Virus (CIV) studies, TruCan Ultra CIV was shown to be highly effective in protecting dogs' lungs and improving clinical signs: Zero vaccinated dogs developed lung lesions post H3N2 challenge2 100% neutralization of 33 currently circulating CIV field isolates1 Proven to reduce viral shedding2,5 Proven safe across multiple breed and ages in field safety study5 "With the recent USDA approval for TruCan Ultra CIV, Elanco continues to lead the charge in innovative animal health solutions," said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. "This vaccine not only offers broad protection against canine influenza but also integrates seamlessly into our Tru Portfolio. Our commitment to delivering safe, effective and advanced solutions reaffirms our position as a trusted partner in animal health, driving forward our mission to enrich lives through the health of animals." Respiratory disease outbreaks can be devastating for patients, their families and veterinary clinics, sometimes leading to facility shutdowns and large financial impact. Canine Infectious Respiratory Disease Complex (CIRDC) is a collection of respiratory diseases of various causative agents, including CIV among others. Certain breeds can be at a higher risk for severe symptoms associated with CIRDC, especially Brachycephalic dogs – dog breeds with short heads, flat faces and snub noses.6 These highly at-risk breeds, which includes French Bulldogs, Bulldogs, Pugs, Boston Terriers and more, continue to grow in popularity with six of the top 25 breeds in the U.S. being brachycephalic.7 Unfortunately, there is a relatively low rate of vaccination for CIV in the U.S. leaving these highly susceptible patients particularly at risk for developing infection when exposed to CIV.8 Patients with the highest risk factors include social dogs, dogs with pre-existing airway disease and those that are unvaccinated or incompletely vaccinated. Brachycephalics strongly benefit from added protection from respiratory disease as they can be life-threatening, with upper respiratory disorders being the cause of death in 17% of those breeds.6 It only takes one patient shedding CIV to spark an outbreak. "With TruCan Ultra CIV, we are improving our ability to protect dogs from serious respiratory disease while remaining committed to helping provide a happier clinic experience for pets and their owners," said Dr. Jennifer Miller, technical veterinarian at Elanco. "This addition to our vaccine portfolio means our veterinarian customers can confidently offer a more complete set of immunizations tailored to the needs of all dogs, ensuring their long-term health and happiness." Elanco's Tru Vaccine line is the first vaccine line recommended by Fear Free®, an organization whose mission is to prevent and alleviate fear, anxiety and stress in pets by inspiring and educating the people who care for them. "Fear, anxiety and stress in pets can stem from many factors, including illness," said Dr. Marty Becker, Founder of Fear Free. "When veterinarians have effective tools to help protect pets from diseases like canine influenza, it can contribute to a smoother, less stressful experience for both pets and their people. Solutions like TruCan Ultra CIV support the goal of reducing fear, anxiety and stress by keeping pets healthier and more comfortable in the veterinary setting." The approval of TruCan Ultra CIV is a key addition to completing Elanco's vaccine portfolio by addressing respiratory disease outbreaks. TruCan Ultra CIV is now available for pre-order and will ship within the next 30 business days. Learn more about TruCan Ultra CIV at *Drs. Becker and Reinero are consultants for Elanco Animal Health. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at 1,2 Elanco Animal Health. Data on File. 3 USDA APHIS. USDA APHIS. Elanco Animal Health. Data on File. 6 The Humane Society of the United States. American Kennel Club. Most Popular Dog Breeds of 2023 - American Kennel Club8 Malter et al. Vaccine 40 (2022) 1001-1009. Trucan, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2025 Elanco or its affiliates. PM-US-25-0067(2) Investor Contact: Tiffany Kanaga (765) 740-0314 Contact: Season Solorio (765) 316-0233 View original content to download multimedia: SOURCE Elanco Animal Health Sign in to access your portfolio